News | July 20, 2009

ATS Medical Announces First Use of the New ATS CryoMaze 10-S Probe for Ablation

July 20, 2009 - ATS Medical Inc. today announced the first commercial use of the new ATS CryoMaze 10-S Surgical Cryoablation Probe for the treatment of cardiac arrhythmias.

The cryoablation procedure was performed by Niv Ad, M.D., chief of cardiac surgery at the Inova Heart and Vascular Institute in Falls Church, Virginia. The ATS CryoMaze 10-S Probe is a linear cryoablation probe that is more rigid than the current ATS CryoMaze probes. The increased support throughout the length of the 10-S probe addresses the preference of some surgeons to have more probe leverage to achieve contact with targeted tissue that is difficult to reach, the company said. In addition, the increased stiffness of the ATS CryoMaze 10-S Probe will optimize the shape retention of the malleable probe, which is particularly useful in minimally invasive procedures.

The new cryoablation probe leverages the second generation, argon-based ATS CryoMaze System that quickly achieves the coldest probe temperatures available for cardiac arrhythmia surgery, the company said. The argon-based cryoablation system routinely reaches probe temperatures of -160 degrees Celsius compared to first generation nitrous-oxide systems, which only reach temperatures of -65 degrees Celsius. The colder probe temperatures provide faster, deeper lesions yielding greater confidence that transmural, linear lesions are being achieved, especially in clinical situations in which varying tissue thickness is the rule, the company said.

The proprietary design utilized in all ATS CryoMaze Probes allows them to be easily shaped by hand without the need for a tool to control the radius of the bends. The probe tip can be repeatedly reshaped intraoperatively to meet the different anatomic requirements of the individual patient and procedure. The "bellows" design of the ATS CryoMaze Probes facilitates this durable probe malleability without kinking and/or fractures.

"The ATS CryoMaze System is very well equipped for minimally invasive stand-alone surgery for atrial fibrillation. The new, more rigid 10-S probe is a great addition that makes it easier to apply lesions and complete full biatrial Maze-III procedures," said Dr. Ad.

For more information: www.atsmedical.com

Related Content

CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
Overlay Init